Actively Recruiting
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Led by ViiV Healthcare · Updated on 2026-10-20
112
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the pharmacokinetics, safety, and tolerability of VH4367310, a cabotegravir prodrug, in healthy adults aged 18 to 55 years. This phase 1, randomized, double-blind, placebo-controlled study aims to assess how the drug behaves in the body and its safety profile when given as a single intramuscular dose. Participants will be randomly assigned to receive either a single injection of VH4367310 or a placebo injection on Day 1. The study uses a sequential design to evaluate increasing doses and monitors participants up to 72 weeks to assess drug concentration levels and safety outcomes. During the study, participants will undergo medical evaluations and monitoring for adverse events. Researchers will measure drug levels in the blood, time to peak concentration, and track any drug-related side effects or serious adverse events. The total participation duration can be up to 72 weeks, allowing long-term safety and drug behavior observation.
CONDITIONS
Brief Title
A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here